Tazemetostat
Tazverik (tazemetostat) is a small molecule pharmaceutical. Tazemetostat was first approved as Tazverik on 2020-01-23. The pharmaceutical is active against histone-lysine N-methyltransferase EZH2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| tazverik | New Drug Application | 2024-08-15 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
TAZEMETOSTAT HYDROBROMIDE, TAZVERIK, EPIZYME INC | |||
| 2027-06-18 | ODE-314 | ||
| 2027-01-23 | ODE-299 | ||
| 2025-01-23 | NCE | ||
| 2023-06-18 | I-835, I-836 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Tazemetostat Hydrobromide, Tazverik, Epizyme Inc | |||
| 10786511 | 2035-12-19 | DP | |
| 9889138 | 2035-10-16 | U-2736, U-2852, U-2853 | |
| 10369155 | 2035-10-16 | U-2736, U-2852, U-2853 | |
| 9688665 | 2034-08-22 | U-2736 | |
| 8410088 | 2034-01-23 | DS, DP | |
| 9394283 | 2033-04-11 | DS, DP | U-2852, U-2853 |
| 10245269 | 2033-04-11 | U-2737, U-2851, U-2854 | |
| 10821113 | 2033-04-11 | DS, DP | |
| 11491163 | 2033-04-11 | U-2736, U-2852, U-2853 | |
| 11052093 | 2032-04-13 | DS, DP | U-2736, U-2852, U-2853 |
| 8691507 | 2031-09-12 | U-2852 | |
| 8765732 | 2031-09-12 | U-2852, U-2853 | |
| 8895245 | 2031-09-12 | U-2852 | |
| 9090562 | 2031-09-12 | DS, DP | |
| 9175331 | 2031-09-12 | U-2852 | |
| 9333217 | 2031-09-12 | U-2852 | |
| 9334527 | 2031-09-12 | U-2852 | |
| 9549931 | 2031-09-12 | U-2736, U-2852, U-2853 | |
| 9855275 | 2031-09-12 | U-2736 | |
| 9949999 | 2031-09-12 | U-2851 | |
| 10155002 | 2031-09-12 | U-2736 | |
| 10420775 | 2031-09-12 | U-2736, U-2852, U-2853 | |
HCPCS
No data
Clinical
Clinical Trials
57 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 1 | 3 | — | — | — | 4 |
| Follicular lymphoma | D008224 | — | C82 | — | 2 | — | — | — | 2 |
| B-cell lymphoma | D016393 | — | — | 1 | 1 | — | — | — | 2 |
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | — | 1 | — | — | — | 1 |
| T-cell lymphoma | D016399 | — | — | — | 1 | — | — | — | 1 |
| Immunoblastic lymphadenopathy | D007119 | EFO_1001350 | C86.5 | — | 1 | — | — | — | 1 |
| Enteropathy-associated t-cell lymphoma | D058527 | — | C86.2 | — | 1 | — | — | — | 1 |
| T-cell lymphoma peripheral | D016411 | — | — | — | 1 | — | — | — | 1 |
| Intestinal diseases | D007410 | — | K63.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tazemetostat |
| INN | tazemetostat |
| Description | Tazemetostat, sold under the brand name Tazverik, is a medication used for the treatment of adults and adolescents aged 16 years and older with metastatic (when cancer cells spread to other parts of the body) or locally advanced (when cancer has grown outside the organ it started in, but has not yet spread to distant parts of the body) epithelioid sarcoma not eligible for complete resection (surgically removing all of a tissue, structure, or organ).
|
| Classification | Small molecule |
| Drug class | enzyme inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1 |
Identifiers
| PDB | — |
| CAS-ID | 1403254-99-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3414621 |
| ChEBI ID | — |
| PubChem CID | 66558664 |
| DrugBank | DB12887 |
| UNII ID | Q40W93WPE1 (ChemIDplus, GSRS) |
Target
Agency Approved
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Tazemetostat – Epizyme
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,473 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,261 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use